Nucleic Acid Isolation, Quantitation, And Purification Market Size and Share
Market Overview
| Study Period | 2019 - 2030 |
|---|---|
| Market Size (2025) | USD 5.59 Billion |
| Market Size (2030) | USD 8.78 Billion |
| Growth Rate (2025 - 2030) | 9.44% CAGR |
| Fastest Growing Market | Asia-Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players
*Disclaimer: Major Players sorted in no particular order Image © Mordor Intelligence. Reuse requires attribution under CC BY 4.0. |
|
Nucleic Acid Isolation, Quantitation, And Purification Market Analysis by Mordor Intelligence
The Nucleic Acid Isolation, Quantitation, And Purification Market size is estimated at USD 5.59 billion in 2025, and is expected to reach USD 8.78 billion by 2030, at a CAGR of 9.44% during the forecast period (2025-2030).
Demand rises as clinical laboratories embed next-generation sequencing into routine oncology workflows, national genomics programs expand sample throughput, and automation curbs staffing shortages. DeepMind’s AlphaGenome has shown the capacity to read 1 million DNA bases in a single run, underscoring how extraction quality now directly influences downstream analytics[1]Ewen Callaway, “DeepMind’s AI Cracks Millions of DNA Letters,” Nature, nature.com. Magnetic bead systems, improved microfluidics and point-of-care formats reinforce this shift by cutting contamination and hands-on time. Capital inflows from biopharmaceutical firms and public research agencies sustain product development across high-throughput platforms, kits and consumables.
Key Report Takeaways
- By technology, magnetic bead-based purification led with 52.1% revenue share in 2024; the segment is projected to expand at an 11.4% CAGR through 2030.
- By product, kits and reagents accounted for 48.3% of 2024 sales, while equipment records the fastest growth at an 11.8% CAGR to 2030.
- By application, genomic DNA isolation held 20.6% share in 2024; microRNA isolation is advancing at an 11.7% CAGR through 2030.
- By end-user, the pharmaceutical and biotechnology sector captured 43.3% of demand in 2024, whereas contract research organizations are set to grow at a 12.4% CAGR.
- By geography, North America retained 42.4% market share in 2024, while Asia-Pacific is on track for a 10.4% CAGR up to 2030.
Global Nucleic Acid Isolation, Quantitation, And Purification Market Trends and Insights
Driver Impact Analysis
| Driver | % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| Surge in clinical-grade NGS demand | +2.8% | North America, Europe, global roll-out | Medium term (2-4 years) |
| National genomics initiatives | +2.1% | US, Australia, UK, global networks | Long term (≥ 4 years) |
| Increased molecular-biology R&D funding | +1.9% | North America, Europe, expanding Asia-Pacific | Medium term (2-4 years) |
| Workflow automation and high-throughput kits | +1.6% | Mature markets worldwide | Short term (≤ 2 years) |
| Microfluidic extraction for PoC devices | +0.7% | Core Asia-Pacific, spill-over to Middle East-Africa | Medium term (2-4 years) |
| Synthetic biology and CRISPR screening boom | +0.3% | North America, Europe, early Asia-Pacific uptake | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
Surge in Clinical-Grade NGS Demand
Growing use of NGS in oncology raises extraction specifications for formalin-fixed and liquid biopsy samples. Labcorp reports threefold better DNA quality from FFPE tissue when using focused acoustics instruments that minimize fragmentation. Liquid biopsy assays require purification systems able to enrich circulating tumor DNA constituting under 1% of total cell-free DNA. Suppliers therefore price premium kits that safeguard integrity, reduce PCR inhibitors and match regulatory documentation for clinical accreditation.
National Genomics Initiatives
Government sequencing programs keep order volumes stable by standardizing high-throughput protocols. Australia’s Genomics Health Futures Mission has committed USD 500.1 million for more than 200 000 citizens, fuelling demand for automated bead platforms that can process diverse blood and tissue inputs. Similar multi-omics efforts in the US and UK reinforce global harmonization, encouraging vendors to ship pre-validated chemistries that deliver consistent yield across distributed sites.
Increased R&D Funding in Molecular Biology
The NIH earmarked USD 3.1 billion for genomic medicine research, enabling laboratories to replace manual columns with robotic workflows that raise reproducibility[2]National Institutes of Health, “Fiscal Year 2025 Budget for Genomic Medicine,” nih.gov. Grants favour multi-omics studies that co-purify DNA, RNA and proteins, spurring innovation in integrated kits that minimize batch variation. Continuous funding also underwrites validation studies that shorten regulatory review for extraction consumables.
Microfluidic Extraction for PoC Devices
Paper-based and chip-scale modules now bind nucleic acids without power-hungry centrifuges. The PRECISE card separates plasma and purifies viral RNA from whole blood in one step[3]J. Zhang et al., “PRECISE Plasma-On-Chip Device,” Royal Society of Chemistry, rsc.org. Such devices allow frontline clinics to run infectious-disease assays inside 30 minutes, particularly in low-resource regions where laboratory infrastructure is scarce.
Restraints Impact Analysis
| Restraints Impact Analysis | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
|---|---|---|---|
| High instrument and reagent costs | −1.8% | Global, acute in cost-sensitive regions | Short term (≤ 2 years) |
| Low penetration in emerging markets | −1.2% | Asia-Pacific, Latin America, Africa | Medium term (2-4 years) |
| Resin and silica supply-chain risks | −0.9% | Concentrated Asian production | Short term (≤ 2 years) |
| Hazardous waste-disposal regulation tightening | −0.6% | Primarily North America and Europe | Long term (≥ 4 years) |
| Source: Mordor Intelligence | |||
High Instrument & Reagent Costs
Automated extractors can cost USD 100 000–500 000 and consumables add USD 10–50 per sample, limiting adoption in smaller labs. Low-cost alternatives such as filter paper-spin columns have reduced per-sample expense while retaining adequate purity. Some vendors now market reusable resin cartridges and long-life beads to trim operating budgets.
Low Penetration in Emerging Markets
Infrastructure gaps delay uptake of gene-based diagnostics in low- and middle-income countries. Only 5 of 32 approved gene therapies are presently accessible in these regions, highlighting the need for equipment-free extraction that tolerates ambient temperatures. Indian manufacturers are piloting protocols that drive CAR-T costs under USD 50 000, a move that could stimulate demand for affordable purification kits.
Segment Analysis
By Technology: Magnetic Bead Dominance Increases Automation
Magnetic beads delivered the largest contribution to the nucleic acid isolation and purification market size, with 52.1% of 2024 revenue and an 11.4% growth trajectory to 2030. This format binds DNA or RNA to silica-coated beads under chaotropic salts, then allows magnet-assisted washing that avoids centrifugation. Workflow speed improves further with formulations such as Cytiva’s guanidinium-thiocyanate chemistry, which inhibits nucleases while ensuring high recovery.
Column-based kits still serve manual setups because their cost per extraction remains lower, yet adoption declines in high-throughput labs. New bead protocols like SHIFT-SP reach near-complete recovery inside seven minutes, supporting clinical turnaround demands. Their compatibility with liquid handlers anchors their long-term advantage.
Note: Segment shares of all individual segments available upon report purchase
By Product: Equipment Upswing Strengthens Automation
Kits and reagents secured 48.3% of 2024 sales, reflecting routine replenishment cycles in diagnostics and research. However, equipment revenue grows fastest at 11.8% CAGR as laboratories invest in robotic extractors that enforce standardization. Beckman Coulter’s OptiMATE Gradient Maker cut ultracentrifugation from three days to six hours, underscoring how instrumentation improves virus-vector workflows.
Spectrophotometers and fluorometers meet stricter quality-control rules that accompany clinical sequencing. Revvity’s chemagic 360 spans 50 µl to 18 ml inputs, pairing software tracking with barcode integration for audit readiness. Consumables such as tips and magnetic rods keep recurring revenues resilient.
By Application: MicroRNA Isolation Accelerates
Genomic DNA purification represented 20.6% of the nucleic acid isolation and purification market share in 2024. Yet microRNA extraction logs the highest 11.7% CAGR as liquid biopsy assays widen adoption. High-throughput microfluidic chips have achieved 90% sensitivity for a seven-marker panel that screens non-small-cell lung cancer, demanding kits that preserve short fragments.
mRNA isolation retains relevance after vaccine successes, while plasmid DNA systems cater to synthetic-biology cloning and gene-therapy seed stock. PCR clean-up kits benefit from next-generation sequencing workflows that need adapter-dimer removal. Biobanking protocols rely on unified chemistries that maintain sample stability over decades for retrospective studies.
Note: Segment shares of all individual segments available upon report purchase
By End-User: CRO Expansion Reshapes Demand
Pharmaceutical and biotechnology companies commanded 43.3% of spending in 2024, with pipelines embracing genomic biomarkers. Contract research organizations will, however, grow at a 12.4% CAGR as sponsors outsource high-complexity extraction to control fixed costs. Tecan and BioSkryb’s single-cell multi-omics package demonstrates how CROs combine automation with advanced analytics to deliver overnight results.
Hospitals remain steady adopters for routine virology and oncology tests, while academic institutes spearhead pilot protocols that later migrate into regulated environments. Vendors nurture these relationships through grant-friendly pricing models and co-development projects.
Geography Analysis
North America retained 42.4% of the nucleic acid isolation and purification market in 2024 thanks to NIH-funded translational genomics, dense biotech clusters and an FDA decision to reclassify high-risk in-vitro diagnostics to Class II, trimming approval timelines. The United States anchors sales, while Canadian and Mexican labs enlarge regional throughput with cross-border clinical-trial activity.
Europe follows with harmonized regulatory frameworks that ease multi-nation research. Germany, the UK and France command instrument procurements driven by established pharmaceutical manufacturing. Wellcome Trust funding of population biobanking sustains demand for automated bead platforms that ensure data integrity across consortium sites. Emphasis on data privacy increases sales of software-embedded extractors that log sample identity.
Asia-Pacific is projected to post a 10.4% CAGR through 2030, fastest worldwide. China’s pharmaceutical policy backs local nucleic acid drug production, fostering large reagent orders, while India’s cost-efficient gene-therapy initiatives encourage adoption of flexible microfluidic kits. Australia’s Genomics Health Futures Mission adds institutional budgets for high-throughput sequencers and extraction robots. Japan and South Korea emphasize precision medicine, lifting demand for high-purity, multi-analyte purification consumables.
Competitive Landscape
Industry consolidation continues as leaders widen portfolios. Thermo Fisher Scientific is acquiring Solventum’s purification and filtration unit for USD 4.1 billion, integrating upstream cell-culture clarification with nucleic acid cleanup. Danaher merged Cytiva and Pall into a USD 7.5 billion bioprocess group that now bundles bead resins, columns and automated instruments across gene therapy workflows.
Emerging players leverage cost-reduction to penetrate price-sensitive segments. Paper-based kits that run at room temperature open fresh markets in field diagnostics, applying ambient-stable chemistries that sidestep cold chains. QIAGEN recorded USD 1.97 billion revenue in 2024, with consumables forming 88% of sales, illustrating the market’s recurring-revenue structure. Vendors incorporate cloud-linked software to lock-in users through protocol libraries, while CRISPR-ready kits and point-of-care microfluidic modules create new differentiation points.
Nucleic Acid Isolation, Quantitation, And Purification Industry Leaders
-
Thermo Fisher Scientific, Inc.
-
F. Hoffmann-La Roche AG
-
Agilent Technologies
-
Bio-Rad Laboratories Inc.
-
Merck KGaA
- *Disclaimer: Major Players sorted in no particular order
Recent Industry Developments
- June 2025: Illumina acquired SomaLogic for USD 350 million to expand proteomics and integrate multi-omics sequencing solutions.
- April 2025: QIAGEN disclosed plans for three sample-prep instruments—QIAmini, QIAsymphony Connect and QIAsprint Connect—covering 24 to 192-sample batch sizes.
- April 2025: Beckman Coulter Life Sciences released OptiMATE Gradient Maker, cutting AAV purification from three days to six hours.
- March 2025: Beckman Coulter partnered with Rarity Bioscience to distribute superRCA assays for sensitive mutation detection in liquid biopsy workflows.
- February 2025: Thermo Fisher Scientific announced the USD 4.1 billion Solventum purchase, adding filtration and purification assets.
Research Methodology Framework and Report Scope
Market Definitions and Key Coverage
Our study defines the nucleic acid isolation, quantitation, and purification market as revenue generated by spin-column kits, magnetic-bead platforms, dedicated reagents, and compact spectro- or fluorometric readers that release DNA or RNA from biological material, verify yield or purity, and hand over clean molecules for downstream work in clinical, research, and industrial laboratories.
Scope exclusion: Protein or peptide clean-up consumables, stand-alone sequencers, PCR thermocyclers, and service fees are not counted.
Segmentation Overview
- By Technology
- Column-based Purification
- Magnetic Bead-based Purification
- Reagent-based Purification
- By Product
- Kits & Reagents
- NA Isolation & Purification Kits
- NA Quantitation Kits
- DNA Quantitation Kits
- RNA Quantitation Kits
- Equipment
- NA Isolation & Purification Instruments
- NA Quantitation Instruments
- Spectrophotometer
- Fluorometer
- Other Products
- Kits & Reagents
- By Application
- Total RNA Isolation & Purification
- mRNA Isolation & Purification
- microRNA Isolation & Purification
- Plasmid DNA Isolation & Purification
- Genomic DNA Isolation & Purification
- Blood DNA Isolation & Purification
- PCR Clean-up
- Biobanking
- Clinical Research
- Forensics
- Drug Development
- Other Applications
- By End-user
- Hospitals
- Academia
- Pharmaceutical / Biotechnology Industry
- CRO
- Geography
- North America
- United States
- Canada
- Mexico
- Europe
- Germany
- United Kingdom
- France
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- Middle East & Africa
- GCC
- South Africa
- Rest of Middle East & Africa
- South America
- Brazil
- Argentina
- Rest of South America
- North America
Detailed Research Methodology and Data Validation
Primary Research
Mordor analysts spoke with laboratory managers, procurement heads at biopharma plants, and principal investigators across North America, Europe, Asia-Pacific, and Latin America. Their insights on kit pull-through, extractor uptime, and regional discounting let us refine assumptions drawn from desk work.
Desk Research
We mapped demand through WHO genomic-surveillance dashboards, OECD biotech spending tables, and UN Comtrade HS-3002 shipment records, and then reviewed AACC and BIO white papers to gauge laboratory adoption. Patent families on bead chemistries accessed via Questel, PubMed meta-analyses, and supplier 10-Ks gathered with D&B Hoovers and Dow Jones Factiva revealed technology diffusion and price ladders. This list is illustrative; numerous other open and paid references informed our baseline.
Market-Sizing & Forecasting
We apply a hybrid top-down-bottom-up logic. Global molecular-biology reagent imports are rebuilt, filtered to nucleic-acid items, then reconciled with sampled kit volumes and installed extraction workstations. Core drivers, installed base expansion, daily run rates, sequencing throughput, national genomics funding, and instrument ASP progression feed a multivariate regression that shapes the 2025-2030 outlook. Scenario buffers absorb policy or funding shocks highlighted by experts.
Data Validation & Update Cycle
Outputs pass double-analyst review, variance checks against external indices, and quarterly currency audits before sign-off. We refresh every twelve months and issue interim updates whenever large tenders, recalls, or regulatory shifts emerge.
Why Mordor's Nucleic Acid Isolation, Quantitation, And Purification Baseline Remains Reliable
Published estimates often diverge because firms choose unequal product baskets, price ladders, and refresh tempos.
According to Mordor Intelligence, we include only nucleic-acid consumables and instruments, convert sales every quarter, and revisit each driver yearly, which tightens comparability.
Benchmark comparison
| Market Size | Anonymized source | Primary gap driver |
|---|---|---|
| USD 5.59 B | Mordor Intelligence | - |
| USD 6.17 B | Global Consultancy A | Counts broader molecular consumables and holds ASPs flat |
| USD 6.62 B | Industry Publisher B | Extrapolates supplier revenue at 2024 exchange rates |
These contrasts show how disciplined scope selection, fresh pricing inputs, and field validation give decision makers a transparent and dependable baseline they can trust.
Key Questions Answered in the Report
What is the current size of the nucleic acid isolation and purification market?
The market produced USD 5.59 billion in revenue during 2025 and is projected to climb to USD 8.78 billion by 2030 at a 9.4% CAGR.
Which technology leads the nucleic acid isolation and purification market?
Magnetic bead-based purification held 52.1% of 2024 revenue and is expanding fastest due to compatibility with laboratory automation.
Why is microRNA isolation growing so quickly?
Liquid biopsy adoption in oncology needs sensitive microRNA extraction, driving this segment at an 11.7% CAGR through 2030.
Which region is growing fastest?
Asia-Pacific is forecast to advance at a 10.4% CAGR as China, India, Japan and Australia scale precision-medicine programs.
How does automation influence purchasing decisions?
Robotic extractors reduce hands-on time and errors, prompting laboratories to shift capex toward equipment that integrates magnetic bead kits and software-guided protocols.
What restrains wider adoption in emerging markets?
High capital costs and limited laboratory infrastructure slow deployment, though cost-effective paper-based and room-temperature protocols are easing barriers.
Page last updated on:
